Soligenix (SNGX) Stock Price, News & Analysis

Company Overview

Soligenix, Inc. is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions. In its Biodefense division, Soligenix is advancing vaccine candidates and antitoxins for agents such as ricin and anthrax, utilizing its RiVax platform and specialized formulation systems to enhance immunogenicity and stability. Within its Orphan Drug division, the lead candidates include SGX942 (dusquetide), an innate defense regulator in late‐stage development for the prevention and treatment of oral mucositis in head and neck cancer patients, and SGX301 (synthetic hypericin), a photodynamic therapy designed for the treatment of cutaneous T‐cell lymphoma.

Soligenix employs collaborations and funding agreements with U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the National Institutes of Health (NIH), to support its biodefense programs and accelerate clinical development. The company’s technology platforms enable the delivery of targeted immune modulation and improved safety profiles, positioning its candidates for both civilian and military medical countermeasure applications.

Founded in 2004 and headquartered in Princeton, New Jersey, Soligenix operates primarily within the United States. The executive leadership team is led by President and Chief Executive Officer Christopher J. Schaber, who brings extensive experience in guiding clinical development and forging strategic partnerships. Soligenix remains committed to advancing its portfolio of specialized therapies and vaccines to serve underserved patient populations and bolster national biosecurity preparedness.

Key Stats

• Today's Range: $0.36 to $0.38
• 50-Day Range: $0.35 to $0.97
• 52-Week Range: $0.28 to $6.23
• Volume: 149,067 shs
• Average Volume: 415,445 shs
• Market Capitalization: $5.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Soligenix Stock Analysis - MarketRank™

Soligenix scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Soligenix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Soligenix has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Soligenix are expected to grow in the coming year, from ($0.90) to ($0.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Soligenix is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Soligenix is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Soligenix has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.36% of the float of Soligenix has been sold short.

Short Interest Ratio / Days to Cover

Soligenix has a short interest ratio ("days to cover") of 1.09, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Soligenix has recently increased by 18.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Soligenix does not currently pay a dividend.

Dividend Growth

Soligenix does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: N/A

News Sentiment

Soligenix has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Soligenix this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for SNGX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Soligenix to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Soligenix insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.05% of the stock of Soligenix is held by insiders.

Percentage Held by Institutions

3.60% of the stock of Soligenix is held by institutions.

Company Calendar

• Last Earnings: 5/08/2026
• Today: 7/26/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNGX
• CIK: 812796
• Web: www.soligenix.com
• Phone: (609) 538-8200
• Fax: 609-452-6467
• Employees: 20
• Year Founded: 1987

Profitability

• EPS (Trailing Twelve Months): ($1.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -244.73%
• Return on Assets: -131.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.81
• Quick Ratio: 1.81

Sales & Book Value

• Annual Sales: $120 thousand
• Price / Sales: 45.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.52 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 14,820,000
• Free Float: 14,372,000
• Market Cap: $5.50 million
• Optionable: Not Optionable
• Beta: 1.92